Xanodyne (Rights to Amicar) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Xanodyne (Rights to Amicar) General Information

Description

Drug formulation for treatment of bleeding disorder. The drug is used for treatment for bleeding disorder in case of surgical complication.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • One Riverfront Place
  • Newport, KY 41071
  • United States
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Acquirer
Corporate Office
  • One Riverfront Place
  • Newport, KY 41071
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xanodyne (Rights to Amicar) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xanodyne (Rights to Amicar)‘s full profile, request access.

Request a free trial

Xanodyne (Rights to Amicar) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xanodyne (Rights to Amicar)‘s full profile, request access.

Request a free trial

Xanodyne (Rights to Amicar) FAQs

  • Where is Xanodyne (Rights to Amicar) headquartered?

    Xanodyne (Rights to Amicar) is headquartered in Newport, KY.

  • What industry is Xanodyne (Rights to Amicar) in?

    Xanodyne (Rights to Amicar)’s primary industry is Buildings and Property.

  • Is Xanodyne (Rights to Amicar) a private or public company?

    Xanodyne (Rights to Amicar) is a Private company.

  • What is Xanodyne (Rights to Amicar)’s current revenue?

    The current revenue for Xanodyne (Rights to Amicar) is .

  • Who are Xanodyne (Rights to Amicar)’s investors?

    Xanodyne Pharmaceuticals has invested in Xanodyne (Rights to Amicar).

  • When was Xanodyne (Rights to Amicar) acquired?

    Xanodyne (Rights to Amicar) was acquired on 01-Aug-2012.

  • Who acquired Xanodyne (Rights to Amicar)?

    Xanodyne (Rights to Amicar) was acquired by VersaPharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process